Sign in
Active, not recruitingPhase 2/3

Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia

Key facts

Who runs it
Copenhagen Respiratory Research
Where
Denmark4 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
460 people, planned
Started
8 Oct 2026
Expected to end
1 Sept 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Inhaled levofloxacin
  • Standard-of-care / Usual care
Record updated
5 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Hospital admission within 24 hours
  • Clinical suspicion of community-acquired pneumonia necessitating antibiotic treatment; Defined as one or more of the following:; Chest X-ray, CT or ultrasound findings consistent with bacterial pneumonia*; Symptoms consistent with bacterial pneumonia (such as dyspnea, tachypnea, cough or purulent sputum)
  • C-reactive protein >50 mg/L OR central body temperature >38.0 °C OR blood leukocytes ≥10.0×109/L (1-3 of these fulfilled)
  • Age ≥ 18 years
  • Able to give informed consent

Who cannot take part

  • Contraindications for fluoroquinolone treatment, including but not limited to:; Known allergy to fluoroquinolones or a serious adverse reaction when previously treated with a fluoroquinolone; Medical history of myasthenia gravis
  • Significant suspicion of an infection with a focus other than the lungs
  • Reduced kidney function (eGFR < 20 mL/min/1.73 m²)
  • Suspicion of clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) > 480ms)
  • Suspected septic shock defined as MAP < 65 mmHg on sequential measurements despite adequate volume resuscitation
  • Oxygen requirement >4L/min to maintain acceptable peripheral oxygen saturation*
  • Suspected aspiration pneumonia, pulmonary abscess, or pleural empyema / complicated parapneumonic effusion
  • Pregnancy**

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial aims to determine whether treatment with inhaled levofloxacin (an antibiotic) is equal to systemic antibiotic treatment (usual care) for patients admitted to a hospital with community-acquired pneumonia in regards to treatment-effect and safety parameters.

Read full original descriptionShow less

Additionally, this study will assess if treatment with inhaled antibiotics leads to fewer antibiotic side-effects and a more preserved gastro-intestinal microbial environment.

The main question this study aims to answer is:

Does inhaled levofloxacin 240mg twice daily result in comparable days alive and out of hospital at 14 days compared to standard-of-care (usual care) antibiotic treatment for community-acquired pneumonia in admitted patients?

Secondary questions this study aims to answer are:

1. Does treatment with inhaled levofloxacin reduce proportion of patients with antibiotic side-effects? 2. Does treatment with inhaled levofloxacin lead to preserved diversity in the gut microbiome? 3. Is treatment with inhaled levofloxacin comparable with usual care in regards to patient reported outcomes?

The above list is not the complete list of questions this study aims to answer, but serves as highlights.

The 2 groups in the trial

  • Standard-of-care (Control)Existing treatment, for comparison

    Systemic antibiotic treatment

    Treatment: Standard-of-care / Usual care

  • Inhaled levofloxacinTreatment being tested

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Local Antibiotic Delivery for Community Acquired Pneumonia
Record updated
5 November 2026